NMD_Logo3_reg.jpg
NMD Pharma adds new capabilities with several senior recruits to support its growing business and pipeline
July 11, 2024 07:00 ET | NMD Pharma
NMD Pharma adds new capabilities with several senior recruits to support its growing business and pipeline Aarhus, Denmark, 11 July 2024 – NMD Pharma A/S, a clinical-stage biotech company dedicated...
NMD_Logo3_reg.jpg
NMD Pharma adds new capabilities with several senior recruits to support its growing business and pipeline
July 11, 2024 01:00 ET | NMD Pharma
NMD Pharma adds new capabilities with several senior recruits to support its growing business and pipeline Aarhus, Denmark, 11 July 2024 – NMD Pharma A/S, a clinical-stage biotech company dedicated...
NMD_Logo3_reg.jpg
NMD Pharma Receives IND Clearance from the FDA to initiate a Phase 2 Clinical Trial of NMD670 in Charcot-Marie-Tooth disease in the US
June 18, 2024 07:00 ET | NMD Pharma
NMD Pharma Receives IND Clearance from the FDA to initiate a Phase 2 Clinical Trial of NMD670 in Charcot-Marie-Tooth disease in the US Aarhus, Denmark, 18 June 2024 – NMD Pharma A/S, a clinical-stage...
NMD_Logo3_reg.jpg
NMD Pharma Receives IND Clearance from the FDA to initiate a Phase 2 Clinical Trial of NMD670 in Charcot-Marie-Tooth disease in the US
June 18, 2024 01:00 ET | NMD Pharma
NMD Pharma Receives IND Clearance from the FDA to initiate a Phase 2 Clinical Trial of NMD670 in Charcot-Marie-Tooth disease in the US Aarhus, Denmark, 18 June 2024 – NMD Pharma A/S, a clinical-stage...
NMD_Logo3_reg.jpg
NMD Pharma Initiates Phase 2b Trial of NMD670 in Generalized Myasthenia Gravis Patients
June 11, 2024 06:00 ET | NMD Pharma
NMD Pharma Initiates Phase 2b Trial of NMD670 in Generalized Myasthenia Gravis Patients Aarhus, Denmark, 11 June 2024 – NMD Pharma A/S, a clinical-stage biotech company dedicated to developing novel...
NMD_Logo3_reg.jpg
NMD Pharma Initiates Phase 2b Trial of NMD670 in Generalized Myasthenia Gravis Patients
June 11, 2024 01:00 ET | NMD Pharma
NMD Pharma Initiates Phase 2b Trial of NMD670 in Generalized Myasthenia Gravis Patients Aarhus, Denmark, 11 June 2024 – NMD Pharma A/S, a clinical-stage biotech company dedicated to developing...
NMD_Logo3_reg.jpg
NMD Pharma Publishes Comprehensive Data Package for NMD670 in Science Translational Medicine
March 21, 2024 07:00 ET | NMD Pharma
NMD Pharma Publishes Comprehensive Data Package for NMD670 in Science Translational Medicine ClC-1 is a chloride ion channel specifically expressed in skeletal muscle cells that normally dampens...
NMD_Logo3_reg.jpg
NMD Pharma Publishes Comprehensive Data Package for NMD670 in Science Translational Medicine
March 21, 2024 02:00 ET | NMD Pharma
NMD Pharma Publishes Comprehensive Data Package for NMD670 in Science Translational Medicine ClC-1 is a chloride ion channel specifically expressed in skeletal muscle cells that normally dampens...
NMD_Logo3_reg.jpg
NMD Pharma announces poster and oral presentations on skeletal muscle targeted ClC-1 therapy at two leading neuromuscular disease conferences
March 01, 2024 14:00 ET | NMD Pharma
NMD Pharma announces poster and oral presentations on skeletal muscle targeted ClC-1 therapy at two leading neuromuscular disease conferences ClC-1 is a chloride ion channel specifically expressed...
NMD_Logo3_reg.jpg
NMD Pharma to present NMD670 clinical data from a Phase I/IIa trial in myasthenia gravis at the 28th International Annual Congress of the World Muscle Society
October 03, 2023 07:00 ET | NMD Pharma
NMD Pharma to present NMD670 clinical data from a Phase I/IIa trial in myasthenia gravis at the 28th International Annual Congress of the World Muscle Society NMD Pharma will show the first ever...